{"success":true,"data":{"pressRelease":{"id":"2961","rtpr_id":"nACSCGQjba","ticker":"LEXX","exchange":"NASDAQ","all_tickers":["LEXX"],"title":"Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales","author":"ACCESSWIRE","published_at":"2026-04-21T13:10:00.420Z","article_body":"600,000 New Wegovy® Pill Prescriptions Written in First Two Months\n\nKELOWNA, BC / ACCESS Newswire (https://www.accessnewswire.com/) / April 21,\n2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the \"Company\" or \"Lexaria\"), a\nglobal innovator in drug delivery platforms, provides this update of\nadditional recent developments in the fast-moving glucagon-like peptide-1\n(\"GLP-1\") oral (or \"pill\") market.\n\nThe GLP-1 oral pill sector is growing much faster in 2026 than expected, and\nfaster than the pre-existing GLP-1 injectable sector. The industry's\nfirst-ever GLP-1 pill for weight loss, Wegovy(®), was approved by the US Food\nand Drug Administration (\"FDA\") on December 22, 2025 and launched in the US\n(https://pr.report/ktum) in January 2026. Prior to that, Rybelsus(®) was the\nonly FDA approved GLP-1 drug available in pill form, but it was approved for\ndiabetes control and only used secondarily (or, \"off label\") for weight loss.\n\nWithin less than the first two months of its launch, Novo Nordisk(®) had\ndisclosed that over 600,000 prescriptions for the Wegovy(®) pill had been\nwritten\n(https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html?&qsearchterm=novo%20nordisk),\nand will report on its first-quarter sales including the Wegovy(®) pill in\nMay. Both the Wegovy(®) injectable and the Wegovy(®) pill contain the same\nactive drug: semaglutide, with which Lexaria has conducted extensive testing\nto determine compatibility with Lexaria's DehydraTECH(™) technology.\n\nAccording to Global Data Healthcare (https://pr.report/ktun), 51% of the\ngrowth in Wegovy(®) revenue between 2026 and 2031 is expected to come from\nthe pill format, with injectable semaglutide expected to reach peak revenue in\n2030, when Novo Nordisk's Wegovy(®) semaglutide franchise is expected to\nreach $15.9 billion in annual revenue. This will be quite an achievement since\n2025 semaglutide revenue derived from Wegovy(®) was 100% in the injectable\ncategory, whereas 2031 revenue from Wegovy(®) products is expected to be 17%\nfrom pills.\n\nAs Lexaria's press release of March 24 (https://pr.report/ktuo) noted, TD\nCowen(®) raised their previous 2030 sales forecast (https://pr.report/ktup)\nof the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis\nis forecasting sales (https://pr.report/ktuq) of $180 billion by 2035, while\nUBS Investment Bank (https://pr.report/ktur)(®) expects 2029 GLP-1 sales to\nreach $126 billion.\n\nIt is not possible to know in advance, what overall portion of the GLP-1\nmarket will be captured by the oral pill format vs. the traditional injectable\nformat; but, if the Wegovy(®) based semaglutide revenue projections are any\nindication, it could certainly be 17% or higher within a few short years of\nproduct launch. In fact, according to a Novo Nordisk(®) executive\n(https://pr.report/ktus), oral GLP-1 drugs may account for as much as 33% of\nthe broader GLP-1 market by that time. Based on the various GLP-1 revenue\nforecasts ranging from $101 billion to $180 billion, this could imply an oral\npill sector ranging in size from $17 billion to $60 billion by the mid 2030's.\n\nThis oral pill GLP-1 market is the specific market sector that Lexaria's\ntechnology is focused on. As noted within an article\n(https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html?&qsearchterm=novo%20nordisk)\nappearing on CNBC, \"Novo Nordisk's new Wegovy(®) GLP-1 pill appears to be\nexpanding the obesity treatment market, drawing in new patients rather than\nconverting existing ones from injections.\" If this proves to be a sustainable\ntrend, then a successful GLP-1 pill sector could power the broader GLP-1\nmarket to become even larger than original projections and provide enhanced\nopportunities for Lexaria's DehydraTECH(™).\n\nThe onset of GLP-1 drugs has radically changed the diabetes and weight-loss\nmarket sectors. The more recent onset of the GLP-1 oral pill sector is now\ndriving revenues faster and further than injectable GLP-1 drugs alone.\nLexaria's DehydraTECH(™) has demonstrated performance enhancing abilities\nacross three prominent GLP-1 drugs: semaglutide, tirzepatide and liraglutide;\nand Lexaria's announced 2026 Research & Development program intends to explore\nDehydraTECH's possible expanded applicability to next generation GLP-1 drugs\nincluding, but not limited to, retatrutide and amycretin\n(https://pr.report/ktut). Lexaria remains in discussions with pharmaceutical\ncompanies related to their potential interest in DehydraTECH(™) for their\noral GLP-1 strategies.\n\nAbout Lexaria Bioscience Corp. & DehydraTECH\nDehydraTECH(™) is Lexaria's patented drug delivery formulation and\nprocessing platform technology which improves the way a wide variety of drugs\nenter the bloodstream, always through oral delivery. DehydraTECH has\nrepeatedly evidenced the ability to increase bio-absorption, reduce\nside-effects, and deliver some drugs more effectively across the blood brain\nbarrier. Lexaria operates a licensed in-house research laboratory and holds a\nrobust intellectual property portfolio with 65 patents granted and additional\npatents pending worldwide. For more information, please visit\nwww.lexariabioscience.com.\n\nCAUTION REGARDING FORWARD-LOOKING STATEMENTS\nThis press release includes forward-looking statements. Statements as such\nterm is defined under applicable securities laws. These statements may be\nidentified by words such as \"anticipate,\" \"if,\" \"believe,\" \"plan,\" \"estimate,\"\n\"expect,\" \"intend,\" \"may,\" \"could,\" \"should,\" \"will,\" and other similar\nexpressions. Such forward-looking statements in this press release include,\nbut are not limited to, statements by the Company relating to the intended use\nof proceeds from the offering and relating to the Company's ability to carry\nout research initiatives, receive regulatory approvals or grants or experience\npositive effects or results from any research or study. Such forward-looking\nstatements are estimates reflecting the Company's best judgment based upon\ncurrent information and involve a number of risks and uncertainties, and there\ncan be no assurance that the Company will actually achieve the plans,\nintentions, or expectations disclosed in these forward-looking statements. As\nsuch, you should not place undue reliance on these forward-looking statements.\nFactors which could cause actual results to differ materially from those\nestimated by the Company include, but are not limited to, market and other\nconditions, government regulation and regulatory approvals, managing and\nmaintaining growth, the effect of adverse publicity, litigation, competition,\nscientific discovery, the patent application and approval process, potential\nadverse effects arising from the testing or use of products utilizing the\nDehydraTECH technology, the Company's ability to maintain existing\ncollaborations and realize the benefits thereof, delays or cancellations of\nplanned R&D that could occur related to pandemics or for other reasons, and\nother factors which may be identified from time to time in the Company's\npublic announcements and periodic filings with the US Securities and Exchange\nCommission on EDGAR. The Company provides links to third-party websites only\nas a courtesy to readers and disclaims any responsibility for the\nthoroughness, accuracy or timeliness of information at third-party websites.\nThere is no assurance that any of Lexaria's postulated uses, benefits, or\nadvantages for the patented and patent-pending technology will in fact be\nrealized in any manner or in any part. No statement herein has been evaluated\nby the Food and Drug Administration (FDA). Lexaria-associated products are not\nintended to diagnose, treat, cure or prevent any disease. Any forward-looking\nstatements contained in this release speak only as of the date hereof, and the\nCompany expressly disclaims any obligation to update any forward-looking\nstatements or links to third-party websites contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise, except as otherwise required by law.\n\nINVESTOR CONTACT:\n\nGeorge Jurcic - Head of Investor Relations\nir@lexariabioscience.com\nPhone: 250-765-6424, ext 202\n\nSOURCE: Lexaria Bioscience Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-industry-1159254)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSCGQjba","title":"Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales","author":"ACCESSWIRE","ticker":"LEXX","created":"2026-04-21T13:10:00.420Z","tickers":["LEXX"],"exchange":"NASDAQ","article_body":"600,000 New Wegovy® Pill Prescriptions Written in First Two Months\n\nKELOWNA, BC / ACCESS Newswire (https://www.accessnewswire.com/) / April 21,\n2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the \"Company\" or \"Lexaria\"), a\nglobal innovator in drug delivery platforms, provides this update of\nadditional recent developments in the fast-moving glucagon-like peptide-1\n(\"GLP-1\") oral (or \"pill\") market.\n\nThe GLP-1 oral pill sector is growing much faster in 2026 than expected, and\nfaster than the pre-existing GLP-1 injectable sector. The industry's\nfirst-ever GLP-1 pill for weight loss, Wegovy(®), was approved by the US Food\nand Drug Administration (\"FDA\") on December 22, 2025 and launched in the US\n(https://pr.report/ktum) in January 2026. Prior to that, Rybelsus(®) was the\nonly FDA approved GLP-1 drug available in pill form, but it was approved for\ndiabetes control and only used secondarily (or, \"off label\") for weight loss.\n\nWithin less than the first two months of its launch, Novo Nordisk(®) had\ndisclosed that over 600,000 prescriptions for the Wegovy(®) pill had been\nwritten\n(https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html?&qsearchterm=novo%20nordisk),\nand will report on its first-quarter sales including the Wegovy(®) pill in\nMay. Both the Wegovy(®) injectable and the Wegovy(®) pill contain the same\nactive drug: semaglutide, with which Lexaria has conducted extensive testing\nto determine compatibility with Lexaria's DehydraTECH(™) technology.\n\nAccording to Global Data Healthcare (https://pr.report/ktun), 51% of the\ngrowth in Wegovy(®) revenue between 2026 and 2031 is expected to come from\nthe pill format, with injectable semaglutide expected to reach peak revenue in\n2030, when Novo Nordisk's Wegovy(®) semaglutide franchise is expected to\nreach $15.9 billion in annual revenue. This will be quite an achievement since\n2025 semaglutide revenue derived from Wegovy(®) was 100% in the injectable\ncategory, whereas 2031 revenue from Wegovy(®) products is expected to be 17%\nfrom pills.\n\nAs Lexaria's press release of March 24 (https://pr.report/ktuo) noted, TD\nCowen(®) raised their previous 2030 sales forecast (https://pr.report/ktup)\nof the overall GLP-1 sector from $101 billion to $139 billion, Roots Analysis\nis forecasting sales (https://pr.report/ktuq) of $180 billion by 2035, while\nUBS Investment Bank (https://pr.report/ktur)(®) expects 2029 GLP-1 sales to\nreach $126 billion.\n\nIt is not possible to know in advance, what overall portion of the GLP-1\nmarket will be captured by the oral pill format vs. the traditional injectable\nformat; but, if the Wegovy(®) based semaglutide revenue projections are any\nindication, it could certainly be 17% or higher within a few short years of\nproduct launch. In fact, according to a Novo Nordisk(®) executive\n(https://pr.report/ktus), oral GLP-1 drugs may account for as much as 33% of\nthe broader GLP-1 market by that time. Based on the various GLP-1 revenue\nforecasts ranging from $101 billion to $180 billion, this could imply an oral\npill sector ranging in size from $17 billion to $60 billion by the mid 2030's.\n\nThis oral pill GLP-1 market is the specific market sector that Lexaria's\ntechnology is focused on. As noted within an article\n(https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html?&qsearchterm=novo%20nordisk)\nappearing on CNBC, \"Novo Nordisk's new Wegovy(®) GLP-1 pill appears to be\nexpanding the obesity treatment market, drawing in new patients rather than\nconverting existing ones from injections.\" If this proves to be a sustainable\ntrend, then a successful GLP-1 pill sector could power the broader GLP-1\nmarket to become even larger than original projections and provide enhanced\nopportunities for Lexaria's DehydraTECH(™).\n\nThe onset of GLP-1 drugs has radically changed the diabetes and weight-loss\nmarket sectors. The more recent onset of the GLP-1 oral pill sector is now\ndriving revenues faster and further than injectable GLP-1 drugs alone.\nLexaria's DehydraTECH(™) has demonstrated performance enhancing abilities\nacross three prominent GLP-1 drugs: semaglutide, tirzepatide and liraglutide;\nand Lexaria's announced 2026 Research & Development program intends to explore\nDehydraTECH's possible expanded applicability to next generation GLP-1 drugs\nincluding, but not limited to, retatrutide and amycretin\n(https://pr.report/ktut). Lexaria remains in discussions with pharmaceutical\ncompanies related to their potential interest in DehydraTECH(™) for their\noral GLP-1 strategies.\n\nAbout Lexaria Bioscience Corp. & DehydraTECH\nDehydraTECH(™) is Lexaria's patented drug delivery formulation and\nprocessing platform technology which improves the way a wide variety of drugs\nenter the bloodstream, always through oral delivery. DehydraTECH has\nrepeatedly evidenced the ability to increase bio-absorption, reduce\nside-effects, and deliver some drugs more effectively across the blood brain\nbarrier. Lexaria operates a licensed in-house research laboratory and holds a\nrobust intellectual property portfolio with 65 patents granted and additional\npatents pending worldwide. For more information, please visit\nwww.lexariabioscience.com.\n\nCAUTION REGARDING FORWARD-LOOKING STATEMENTS\nThis press release includes forward-looking statements. Statements as such\nterm is defined under applicable securities laws. These statements may be\nidentified by words such as \"anticipate,\" \"if,\" \"believe,\" \"plan,\" \"estimate,\"\n\"expect,\" \"intend,\" \"may,\" \"could,\" \"should,\" \"will,\" and other similar\nexpressions. Such forward-looking statements in this press release include,\nbut are not limited to, statements by the Company relating to the intended use\nof proceeds from the offering and relating to the Company's ability to carry\nout research initiatives, receive regulatory approvals or grants or experience\npositive effects or results from any research or study. Such forward-looking\nstatements are estimates reflecting the Company's best judgment based upon\ncurrent information and involve a number of risks and uncertainties, and there\ncan be no assurance that the Company will actually achieve the plans,\nintentions, or expectations disclosed in these forward-looking statements. As\nsuch, you should not place undue reliance on these forward-looking statements.\nFactors which could cause actual results to differ materially from those\nestimated by the Company include, but are not limited to, market and other\nconditions, government regulation and regulatory approvals, managing and\nmaintaining growth, the effect of adverse publicity, litigation, competition,\nscientific discovery, the patent application and approval process, potential\nadverse effects arising from the testing or use of products utilizing the\nDehydraTECH technology, the Company's ability to maintain existing\ncollaborations and realize the benefits thereof, delays or cancellations of\nplanned R&D that could occur related to pandemics or for other reasons, and\nother factors which may be identified from time to time in the Company's\npublic announcements and periodic filings with the US Securities and Exchange\nCommission on EDGAR. The Company provides links to third-party websites only\nas a courtesy to readers and disclaims any responsibility for the\nthoroughness, accuracy or timeliness of information at third-party websites.\nThere is no assurance that any of Lexaria's postulated uses, benefits, or\nadvantages for the patented and patent-pending technology will in fact be\nrealized in any manner or in any part. No statement herein has been evaluated\nby the Food and Drug Administration (FDA). Lexaria-associated products are not\nintended to diagnose, treat, cure or prevent any disease. Any forward-looking\nstatements contained in this release speak only as of the date hereof, and the\nCompany expressly disclaims any obligation to update any forward-looking\nstatements or links to third-party websites contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise, except as otherwise required by law.\n\nINVESTOR CONTACT:\n\nGeorge Jurcic - Head of Investor Relations\nir@lexariabioscience.com\nPhone: 250-765-6424, ext 202\n\nSOURCE: Lexaria Bioscience Corp.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-industry-1159254)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-04-21T13:10:00.462510135Z","server_sent_at_ms":1776777000462},"received_at":"2026-04-21T13:10:00.520Z","source_url":"https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-expects-oral-glp-1-pills-to-generate-billions-in-new-industry-1159254"},"analysis":null,"durationMs":null,"modelName":null}}